The role of p62 in the mechanism of Cr(VI) carcinogenesis
p62在Cr(VI)致癌机制中的作用
基本信息
- 批准号:9753486
- 负责人:
- 金额:$ 34.43万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-05-08 至 2019-08-22
- 项目状态:已结题
- 来源:
- 关键词:AnimalsAnti-inflammatoryAntioxidantsApoptosisApoptoticAutophagocytosisBCL2 geneBindingCell SurvivalCellsChronicDevelopmentDrug resistanceEpithelialEpithelial CellsExhibitsExposure toGenerationsGenesInflammationInflammatoryInvestigationKnockout MiceLaboratoriesLungMalignant - descriptorMalignant NeoplasmsMeasuresMusNADPH OxidaseNormal CellOccupational ExposureOncogenicOxidative StressPathway interactionsPhosphorylationPlayPoisonProcessPropertyProteinsReactive Oxygen SpeciesResponse ElementsRoleSignal PathwaySignal TransductionStructure of parenchyma of lungTNF geneTRAF6 geneTestingUp-RegulationXenograft Modelanimal tissuecancer cellcarcinogenesiscarcinogenicitycatalasecell transformationchromium hexavalent ionexposed human populationhuman tissueinhibitor/antagonistparticlepromotertranscription factortranscriptometranscriptome sequencingtumortumorigenesis
项目摘要
Although reactive oxygen species (ROS) are considered important in Cr(VI)-induced malignant cell
transformation, the underlying mechanism remains to be investigated. Recent studies show that ROS are
important in the induction of autophagy and subsequently upregulation of p62. Our preliminary results show
that chronic exposure of human bronchial epithelial (BEAS-2B) cells to Cr(VI) upregulated p62 and that chronic
exposure of animals to Cr(VI) particles upregulated this protein in the lung. Forced expression of p62 in BEAS-
2B cells caused malignant transformation of these cells and generated tumor in xenograft model. Thus, it is
likely that in BEAS-2B cells ROS upregulate p62 and its downstream, leading to cell transformation. Our
preliminary studies show that in Cr(VI)-transformed cells p62 was upregulated. Among six main
domains/regions of p62, we will study (a) the TRAF6-binding domain, which binds to TRAF6 and causes its
phosphorylation, leading to activation of NF-κB, and (b) the Keap-interacting region, which binds to Keap1
(Nrf2 inhibitor) and causes constitutive activation of Nrf2. The central hypothesis is that in normal cells Cr(VI)
activates NADPH oxidase, generates ROS, and then upregulates p62, leading to malignant cell transformation
and that in Cr(VI)-transformed cells p62 activates NF-κB through TRAF6-binding domain and causes
constitutive Nrf2 activation through Keap-interacting region and subsequently upregulates its downstream anti-
inflammatory, antioxidant, and anti-apoptotic proteins, resulting in increased survival and tumorigenesis of
these transformed cells. Aim 1 will test the hypothesis that in normal cells Cr(VI) activates NADPH oxidase,
generates ROS, and upregulates p62, leading to malignant cell transformation. We will carry out the following
studies. (a) ROS generated by Cr(VI) upregulate p62. We will inhibit ROS to show the decrease of p62. (b) We
will inhibit ROS or p62 to demonstrate the inhibition of Cr(VI)-induced malignant cell transformation. (c) We will
use whole transcriptome (RNA Seq) analysis to identify p62 downstream genes responsible for Cr(VI)-induced
malignantly transformation. Aim 2 will test the hypothesis that p62 upregulates NF-κB through its TRAF6-
binding domain and that p62 causes constitutive Nrf2 activation through its Keap-interacting region, resulting in
the generation of microenvironment favorable for survival of Cr(VI)-transformed cells and subsequent
tumorigenesis. We will show (a) the role of TRAF6-binding domain in NF-κB activation; (b) the role of Keap-
interacting region in constitutive Nrf2 activation and upregulation of its downstream inflammatory, antioxidant,
and anti-apoptotic proteins; and (c) the role of p62 and its downstream NF-κB and Nrf2 pathways in
tumorigenesis of Cr(VI)-transformed cells. Aim 3 will investigate the role of p62 in the mechanism of Cr(VI)
carcinogenesis using p62 wildtype and knockout mice. We will measure p62 and its downstream proteins in
lung issues of animals chronically exposed to Cr(VI) and of workers occupationally exposed to Cr(VI) to
strengthen the cellular and animal Cr(VI) exposure studies.
尽管活性氧(ROS)在Cr(VI)诱导的恶性细胞中被认为是重要的
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Xianglin Shi其他文献
Xianglin Shi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Xianglin Shi', 18)}}的其他基金
Center for Appalachian Research in Environmental Sciences
阿巴拉契亚环境科学研究中心
- 批准号:
9270969 - 财政年份:2017
- 资助金额:
$ 34.43万 - 项目类别:
Oxidative stress, Cr(VI) carcinogenesis, and prevention
氧化应激、Cr(VI) 致癌作用及预防
- 批准号:
9237917 - 财政年份:2015
- 资助金额:
$ 34.43万 - 项目类别:
Oxidative stress, Cr(VI) carcinogenesis, and prevention
氧化应激、Cr(VI) 致癌作用及预防
- 批准号:
9415389 - 财政年份:2015
- 资助金额:
$ 34.43万 - 项目类别:
Oxidative stress, Cr(VI) carcinogenesis, and prevention
氧化应激、Cr(VI) 致癌作用及预防
- 批准号:
8912686 - 财政年份:2015
- 资助金额:
$ 34.43万 - 项目类别:
Oxidative stress, Cr(VI) carcinogenesis, and prevention
氧化应激、Cr(VI) 致癌作用及预防
- 批准号:
9060377 - 财政年份:2015
- 资助金额:
$ 34.43万 - 项目类别:
Apoptosis resistance and Cr(VI) carcinogenesis
细胞凋亡抵抗和 Cr(VI) 致癌作用
- 批准号:
8765910 - 财政年份:2014
- 资助金额:
$ 34.43万 - 项目类别:
Apoptosis resistance and Cr(VI) carcinogenesis
细胞凋亡抵抗和 Cr(VI) 致癌作用
- 批准号:
9473778 - 财政年份:2014
- 资助金额:
$ 34.43万 - 项目类别:
Apoptosis resistance and Cr(VI) carcinogenesis
细胞凋亡抵抗和 Cr(VI) 致癌作用
- 批准号:
9058060 - 财政年份:2014
- 资助金额:
$ 34.43万 - 项目类别:
相似海外基金
Development of Enhanced Anti-inflammatory Blood Mononuclear Cell Therapy for ARDS and Elucidation of the Molecular Mechanism
ARDS增强抗炎血液单核细胞治疗的进展及分子机制的阐明
- 批准号:
23K07659 - 财政年份:2023
- 资助金额:
$ 34.43万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Exploring therapeutic effects of anti-inflammatory and resolving factors in osteoporosis model mice
探讨抗炎和缓解因子对骨质疏松模型小鼠的治疗作用
- 批准号:
23K15705 - 财政年份:2023
- 资助金额:
$ 34.43万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Investigation of the relation between age-related estradiol fluctuation and pro-/anti-inflammatory effects in transplant immune response.
研究年龄相关雌二醇波动与移植免疫反应中促/抗炎作用之间的关系。
- 批准号:
23K19490 - 财政年份:2023
- 资助金额:
$ 34.43万 - 项目类别:
Grant-in-Aid for Research Activity Start-up
Non-coating anti-microbial, anti-host protein deposition, anti-inflammatory urinary catheter
无涂层抗菌、抗宿主蛋白沉积、抗炎导尿管
- 批准号:
10697567 - 财政年份:2023
- 资助金额:
$ 34.43万 - 项目类别:
Identification and optimization of verapamil as a novel neuroprotective and anti-inflammatory agent for reducing long-term neurological morbidities following organophosphate-induced status epilepticus
维拉帕米作为新型神经保护和抗炎剂的鉴定和优化,用于减少有机磷引起的癫痫持续状态后的长期神经系统发病率
- 批准号:
10727765 - 财政年份:2023
- 资助金额:
$ 34.43万 - 项目类别:
Anti-inflammatory Effects of Hydrogen Gas Produced by Gut Microflora in a Mouse Model of ARDS
肠道菌群产生的氢气对 ARDS 小鼠模型的抗炎作用
- 批准号:
23K08467 - 财政年份:2023
- 资助金额:
$ 34.43万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Knockdown of AdipoR2 Compromises Adiponectin’s Anti-inflammatory Actions by Mainly Promoting a Pro-inflammatory Chemokine and Cytokine Secretory Profile in THP-1 Macrophages
AdipoR2 的敲低主要通过促进 THP-1 巨噬细胞中促炎趋化因子和细胞因子的分泌特征来损害脂联素的抗炎作用
- 批准号:
493138 - 财政年份:2023
- 资助金额:
$ 34.43万 - 项目类别:
Elucidation of anti-inflammatory mechanism of surface layer protein of lactic acid bacteria focusing on its interaction with lipopolysaccharide.
阐明乳酸菌表面层蛋白的抗炎机制,重点关注其与脂多糖的相互作用。
- 批准号:
23K13905 - 财政年份:2023
- 资助金额:
$ 34.43万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
SBIR Phase I: Structure-guided design of anti-inflammatory modulators of protease-activated receptor 1 (PAR1)
SBIR I 期:蛋白酶激活受体 1 (PAR1) 抗炎调节剂的结构引导设计
- 批准号:
2223225 - 财政年份:2023
- 资助金额:
$ 34.43万 - 项目类别:
Standard Grant
Targeting anti-viral and anti-inflammatory responses during ocular HSV-1 infection to prevent vision impairment.
针对眼部 HSV-1 感染期间的抗病毒和抗炎反应,以预防视力障碍。
- 批准号:
10651054 - 财政年份:2023
- 资助金额:
$ 34.43万 - 项目类别:














{{item.name}}会员




